KiraGen was selected as one of 18 teams in the Boston cohort of Nucleate's 2024 Activator program.
The program provided support and access to the Boston biotechnology community as KiraGen developed its early strategy for solid-tumor CAR-T cells using combinatorial gene editing and AI.